Society of Surgical Oncology Annual Meeting | Conference

Adjuvant Nivolumab Improves DFS in Resected Esophageal/Gastroesophageal Junction Cancer
March 24, 2021

The phase 3 CheckMate 577 trial is the first to show a checkpoint inhibitor in the adjuvant setting after trimodality therapy demonstrate a statistically significant and clinically meaningful improvement in disease-free survival in patients with resected esophageal and gastroesophageal junction cancer.

Adjuvant Immunotherapy Produced Survival Benefit for Patients With High-Risk Stage II Melanoma
March 23, 2021

Adjuvant immunotherapy treatment was associated with a significant survival benefit for patients with stage II melanoma in a study presented at the Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care.

Breast pCR, Nodal Status Can Predict Nodal pCR for Specific Cancer Subtypes Treated With Chemotherapy
March 19, 2021

Data presented at the Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care found that breast pCR was predictive of nodal pCR for patients with HER2-positive and triple-negative breast cancer treated with chemotherapy.